These are very useful imo, Kaplan Ob is kinda vague regarding management of cervical cytology and dysplasias.
USPSTF summary:
The USPSTF recommends screening for cervical cancer in women ages 21 to 65 years with cytology (Pap smear) every 3 years or, for women ages 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years.
The USPSTF recommends against screening for cervical cancer in women younger than age 21 years. The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (i.e., cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer
American Society for Colposcopy and Cervical Pathology
U.S. Preventive Services Task Force
The Agency for Healthcare Research and Quality's
Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) on Cytology:
![Rectangle Font Parallel Handwriting Number]()
click image to enlarge
Management of Women with Atypical Squamous Cells - Cannot Exclude High-grade SIL (ASC-H):
![Font Parallel Rectangle Diagram Slope]()
click image to enlarge
Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL)
![Product Rectangle Font Slope Line]()
click image to enlarge
Management of Women with High-grade Squamous Intraepithelial Lesions (HSIL)
![Font Parallel Rectangle Number]()
click image to enlarge
Management of Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia - Grade 1 (CIN 1) and Satisfactory Colposcopy:
![Slope Font Rectangle Material property Parallel]()
click image to enlarge
Management of Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia - Grade 2 and 3 (CIN 2,3):
![Font Parallel Rectangle Number Diagram]()
click image to enlarge
USPSTF:
![Font Material property Parallel Screenshot Number]()
click image to enlarge
Good Luck
USPSTF summary:
The USPSTF recommends screening for cervical cancer in women ages 21 to 65 years with cytology (Pap smear) every 3 years or, for women ages 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years.
The USPSTF recommends against screening for cervical cancer in women younger than age 21 years. The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (i.e., cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer
American Society for Colposcopy and Cervical Pathology
U.S. Preventive Services Task Force
The Agency for Healthcare Research and Quality's
Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) on Cytology:
click image to enlarge
Management of Women with Atypical Squamous Cells - Cannot Exclude High-grade SIL (ASC-H):
click image to enlarge
Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL)
click image to enlarge
Management of Women with High-grade Squamous Intraepithelial Lesions (HSIL)
click image to enlarge
Management of Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia - Grade 1 (CIN 1) and Satisfactory Colposcopy:
click image to enlarge
Management of Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia - Grade 2 and 3 (CIN 2,3):
click image to enlarge
USPSTF:
click image to enlarge
Good Luck
